$377.37
+2.37
(+0.63%)▲
Live
Insights on Argenx Se
Revenue is up for the last 8 quarters, 23.41M → 407.43M (in $), with an average increase of 30.2% per quarter
Netprofit is down for the last 2 quarters, -72.64M → -99.31M (in $), with an average decrease of 36.7% per quarter
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 53.7%
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 214.2%
2.7%
Downside
Day's Volatility :2.7%
Upside
0.0%
13.15%
Downside
52 Weeks Volatility :40.49%
Upside
31.48%
Period | Argenx Se | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -1.97% | 1.7% | 0.0% |
6 Months | -20.55% | 11.3% | 0.0% |
1 Year | -3.97% | 5.4% | 1.3% |
3 Years | 27.97% | 13.9% | -22.1% |
Market Capitalization | 22.2B |
Book Value | $69.22 |
Earnings Per Share (EPS) | -5.17 |
PEG Ratio | 0.0 |
Wall Street Target Price | 478.76 |
Profit Margin | -23.26% |
Operating Margin TTM | -32.75% |
Return On Assets TTM | -6.85% |
Return On Equity TTM | -8.54% |
Revenue TTM | 1.3B |
Revenue Per Share TTM | 0.89 |
Quarterly Revenue Growth YOY | 134.9% |
Gross Profit TTM | -251.8M |
EBITDA | -316.8M |
Diluted Eps TTM | -5.17 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.57 |
EPS Estimate Next Year | 3.97 |
EPS Estimate Current Quarter | -1.7 |
EPS Estimate Next Quarter | -0.86 |
What analysts predicted
Upside of 26.87%
Sell
Neutral
Buy
Argenx Se is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Argenx Se | -5.88% | -20.55% | -3.97% | 27.97% | 211.41% |
Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Argenx Se | NA | NA | 0.0 | -2.57 | -0.09 | -0.07 | NA | 69.22 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Argenx Se | Buy | $22.2B | 211.41% | NA | -23.26% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
FMR Inc
T. Rowe Price Associates, Inc.
Artisan Partners Limited Partnership
Capital World Investors
HHG PLC
venBio Select Advisor LLC
Argenx Se’s price-to-earnings ratio stands at None
Read MoreArgenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.
Organization | Argenx Se |
Employees | 1148 |
CEO | Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc. |
Industry | Health Technology |
Spdr Portfolio Large Cap Etf
$377.37
+0.63%
Canadian National Railway Company
$377.37
+0.63%
Reit Vanguard Etf
$377.37
+0.63%
Airbnb
$377.37
+0.63%
S&p 500 Growth Index Ishares
$377.37
+0.63%
Wisdomtree Us Quality Dividend Gr Etf
$377.37
+0.63%
Constellation Brands Inc.
$377.37
+0.63%
Live Nation Entertainment, Inc.
$377.37
+0.63%
Shopify Inc.
$377.37
+0.63%